InMed Pharmaceuticals reports fiscal 2026 revenue of $3.18M and EPS loss of $3.12
The company reported fiscal 2026 revenue of $3.18 million, largely from discontinued BayMedica commercial operations. Net loss attributable to common shareholders was $13 million, and diluted loss per share was ($3.12).
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.